Guardant Health, Inc. Hits New 52-Week High at $134.66

Guardant Health, Inc. has reached a significant milestone by hitting a new 52-week high of USD 134.66 on June 23, 2026. This achievement underscores the company's remarkable performance over the past year, with a staggering increase of 335.23%, significantly outpacing the S&P 500's growth of 22.24%. As a mid-cap player in the Pharmaceuticals & Biotechnology industry, Guardant Health has demonstrated strong financial metrics, including an impressive return on equity of 413.71%. However, it is important to note that the company is currently loss-making, as indicated by its negative price-to-earnings ratio and a price-to-book ratio of -111.76. Additionally, Guardant Health maintains a debt-to-equity ratio of -3.32, reflecting a unique financial structure. With a market capitalization of USD 11,098 million, Guardant Health continues to position itself as a notable entity within its industry. The stock's journey from a 52-week low of USD 40.36 to its current high illustrates its dynamic performance and resilience in the market.